Inhibrx Gross Profit 2020-2022 | INBX

Inhibrx gross profit from 2020 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Inhibrx Annual Gross Profit
(Millions of US $)
2021 $7
2020 $13
2019 $13
Inhibrx Quarterly Gross Profit
(Millions of US $)
2022-03-31 $1
2021-12-31 $3
2021-09-30 $3
2021-06-30 $1
2021-03-31 $1
2020-12-31 $3
2020-09-30 $6
2020-06-30 $3
2020-03-31 $1
2019-12-31
2019-09-30 $1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.443B $0.007B
Inhibrx Inc. is a clinical-stage biotechnology company. The company's pipeline is focused on oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.938B 9.97
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.718B 16.92
Biohaven Pharmaceutical Holding (BHVN) United States $10.276B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.817B 46.07
Emergent Biosolutions (EBS) United States $1.560B 6.68
Myovant Sciences (MYOV) United Kingdom $1.185B 0.00
Zymeworks (ZYME) Canada $0.306B 0.00
Gelesis Holdings (GLS) United States $0.112B 0.00
Ambrx Biopharma (AMAM) United States $0.102B 0.00
Enzo Biochem (ENZ) United States $0.101B 0.00
SQZ Biotechnologies (SQZ) United States $0.090B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00